文献速递消化系统肿瘤

RAS/BRAF野生型转移性结直肠癌接受帕尼单抗维持治疗患者的负向超选择

Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy.
PubMed 文献 · J Clin Oncol · 2019-09-20

本研究对Valentino试验中199例RAS/BRAF野生型mCRC患者进行回顾性分析,评估原发肿瘤部位和抗EGFR原发耐药罕见变异(PRESSING panel)对预后的影响。结果显示右侧肿瘤和PRESSING阳性患者ORR、PFS和OS均较差,尤其在单药帕尼单抗维持治疗亚组中预后极差。

要点

  • 右侧肿瘤和PRESSING阳性与RAS/BRAF野生型mCRC患者较差的ORR、PFS和OS相关。
  • FU+LV加入帕尼单抗维持治疗的PFS获益与肿瘤部位和PRESSING状态无关。
  • 单药帕尼单抗维持治疗中,右侧或PRESSING阳性患者预后极差。

核心结论

  • 综合评估肿瘤部位和抗EGFR原发耐药分子变异可识别从初始抗EGFR方案获益较差的患者,尤其在单药抗EGFR维持治疗后。

研究设计与样本

  • Valentino试验的预设回顾性分析,纳入199例可评估的RAS/BRAF野生型mCRC患者。
  • 患者随机接受帕尼单抗联合FOLFOX-4诱导后,维持治疗为帕尼单抗联合或不联合FU/LV。

主要发现

  • 左侧和右侧肿瘤分别占85.4%和14.6%,PRESSING阴性和阳性分别占75.4%和24.6%。
  • 单药帕尼单抗维持治疗中,右侧肿瘤患者中位PFS 7.7个月,2年OS率38.5%;PRESSING阳性患者中位PFS 7.4个月,2年OS率47.0%。

关键数值与推荐

  • PRESSING panel包括HER2/MET扩增的IHC和原位杂交,ALK/ROS1/NTRKs/RET融合的IHC联合或不联合RNA测序,HER2/PIK3CAex.20/PTEN/AKT1和低突变等位基因频率RAS突变的NGS,以及微卫星不稳定的多重PCR。

临床怎么用

  • 对RAS/BRAF野生型mCRC患者,可综合评估肿瘤部位和PRESSING状态以指导抗EGFR治疗决策。
  • 右侧肿瘤或PRESSING阳性患者接受单药帕尼单抗维持治疗预后极差,应考虑联合化疗或其他策略。

局限性

  • 回顾性分析,样本量有限。
  • 需要前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We assessed the prognostic/predictive role of primary tumor sidedness and uncommon alterations of anti-epidermal growth factor receptor (EGFR) primary resistance (primary resistance in RAS and BRAF wild-type metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies [PRESSING] panel) in patients with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) who were randomly assigned to panitumumab plus fluorouracil, leucovorin, and oxaliplatin (FOLFOX-4) induction followed by maintenance with panitumumab with or without fluorouracil (FU) plus leucovorin (LV); Valentino trial (ClinicalTrials.gov identifier: NCT02476045). PATIENTS AND METHODS: This prespecified retrospective analysis included 199 evaluable patients with RAS/BRAF wt. The PRESSING panel included the following: immunohistochemistry (IHC) and in situ hybridization for HER2/MET amplification, IHC with or without RNA sequencing for ALK/ROS1/NTRKs/RET fusions, next-generation sequencing for HER2/PIK3CAex.20/PTEN/AKT1 and RAS mutations with low mutant allele fraction, and multiplex polymerase chain reaction for microsatellite instability. PRESSING status (any positive biomarker v all negative) and sidedness were correlated with overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) in the study population and by treatment arm. RESULTS: Overall, left- and right-sided tumors were 85.4% and 14.6%, respectively, and PRESSING-negative and -positive tumors were 75.4% and 24.6%, respectively. At a median follow-up of 26 months, inferior outcomes were consistently observed in right- versus left-sided tumors for ORR (55.2% v 74.1%; P = .037), PFS (8.4 v 11.5 months; P = .026), and OS (2-year rate: 50.2% v 65.1%; P = .062). Similar results were observed in the PRESSING-positive versus PRESSING-negative subgroup for ORR (59.2% v 75.3%; P = .030), PFS (7.7 v 12.1 months; P < .001), and OS (2-year rate: 48.1% v 68.1%; P = .021). The PFS benefit of FU plus LV added to panitumumab maintenance, reported in the study, was independent from sidedness and PRESSING status (interaction for PFS P = .293 and .127, respectively). However, outcomes were extremely poor in patients who received single-agent panitumumab and had right-sided tumors (median PFS, 7.7 months; 2-year OS, 38.5%) or PRESSING-positive tumors (median PFS, 7.4 months; 2-year OS, 47.0%). CONCLUSION: The combined assessment of sidedness and molecular alterations of anti-EGFR primary resistance identified a consistent proportion of patients with RAS/BRAF-wt mCRC who had inferior benefit from initial anti-EGFR-based regimens, particularly after maintenance with single-agent anti-EGFRs.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Morano F, Corallo S, Lonardi S, et al. Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy. J Clin Oncol. 2019. PMID: 31539295. doi:10.1200/JCO.19.01254

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。